только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 7 / 8
Страница 1 / 1

Литература

    1. Roduit C., Frei R., Depner M., Karvonen A.M., Renz H., Braun-Fahrländer C., Schmausser-Hechfellner E., Pekkanen J., Riedler J., Dalphin J.C., von Mutius E., Lauener R.P.; the PASTURE study group, Hyvärinen A., Kirjavainen P., Remes S., Roponen M., Dalphin M.L., Kaulek V., Ege M., Genuneit J., Illi S., Kabesch M., Schaub B., Pfefferle P.I., Doekes G. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood // JAMA Pe­diatr. 2017. Vol. 171, N 7. P. 655–662. DOI: https://doi.org/10.1001/jamapediatrics.2017.0556
    2. Zar H.J., Ehrlich R.I., Workman L., Weinberg E.G. The changing prevalence of asthma, allergic rhinitis and atopic eczema in African ado­lescents from 1995 to 2002 // Pediatr. Allergy Immunol. 2007. Vol. 18, N 7. P. 560–565. DOI: https://doi.org/10.1111/j.1399-3038.2007.00554.x
    3. Odhiambo J.A., Williams H.C., Clayton T.O., Robertson C.F., Asher M.I.; ISAAC Phase Three Study Group. Global variations in preva­­­lence of eczema symptoms in children from ISAAC Phase Three // J. Allergy Clin. Immunol. 2009. Vol. 124, N 6. P. 1251–1258.e23. DOI: https://doi.org/10.1016/j.jaci.2009.10.009
    4. Кубанова А.А., Кубанов А.А., Мелехина Л.Е., Богданова Е.В. Ана­лиз состояния заболеваемости болезнями кожи и подкожной клетчатки в Российской Федерации за период 2003–2016 гг. // Вестник дерматологии и венерологии. 2017. № 6. С. 22–33. DOI: https://doi.org/10.25208/0042-4609-2017-93-6-22-3310.1159/000497383
    5. Кубанов А.А., Богданова Е.В. Организация и результаты оказа­ния медицинской помощи по профилю «дерматовенерология» в Российской Федерации. Итоги 2018 г. // Вестник дерматоло­гии и венерологии. 2019. Т. 95, № 4. C. 8–23. DOI: https://doi.org/10.25208/0042-4609-2019-95-4-8-23
    6. Garmhausen D., Hagemann T., Bieber T., Dimitriou I., Fimmers R., Diepgen T., Novak N. Characterization of different courses of atopic dermatitis in adolescent and adult patients // Allergy. 2013. Vol. 68, N 4. P. 498–506. DOI: https://doi.org/10.1111/all.12112
    7. Barbarot S., Auziere S., Gadkari A., Girolomoni G., Puig L., Simpson E.L., Margolis D.J., de Bruin-Weller M., Eckert L. Epidemiology of atopic dermatitis in adults: Results from an international survey // Allergy. 2018. Vol. 73, N 6. P. 1284–1293. DOI: https://doi.org/10.1111/all.13401
    8. Williams H.C. Epidemiology of atopic dermatitis // Clin. Exp. Der­matol. 2000. Vol. 25, N 7. P. 522–529. DOI: https://doi.org/10.1046/j.1365-2230.2000.00698.x
    9. Pöysä L., Korppi M., Pietikäinen M., Remes K., Juntunen-Back­man K. Asthma, allergic rhinitis and atopic eczema in Finnish children and adolescents // Allergy. 1991. Vol. 46, N 3. P. 161–165. DOI: https://doi.org/10.1111/j.1398-9995.1991.tb00564.x
    10. Leung R., Ho P. Asthma, allergy, and atopy in three south-east Asian populations // Thorax. 1994. Vol. 49, N 12. P. 1205–1210. DOI: https://doi.org/10.1136/thx.49.12.1205
    11. Silverberg J.I., Hanifin J., Simpson E.L. Climatic factors are associated with childhood eczema prevalence in the United States // J. Invest. Dermatol. 2013. Vol. 133, N 7. P. 1752–1759. DOI: https://doi.org/10.1038/jid.2013.19
    12. George A.O. Atopic dermatitis in Nigeria // Int. J. Dermatol. 1989. Vol. 28, N 4. P. 237–239. DOI: https://doi.org/10.1111/j.1365-4362.1989.tb04811.x
    13. Schäfer T., Krämer U., Vieluf D., Abeck D., Behrendt H., Ring J. The excess of atopic eczema in East Germany is related to the intri­nsic type // Br. J. Dermatol. 2000. Vol. 143, N 5. P. 992–998. DOI:
      https://doi.org/10.1046/j.1365-2133.2000.03832.x
    14. Sausenthaler S., Kompauer I., Borte M., Herbarth O., Schaaf B., Berg A., Zutavern A., Heinrich J.; LISA Study Group. Margarine and but­ter consumption, eczema and allergic sensitization in children. The LISA birth cohort study // Pediatr. Allergy Immunol. 2006. Vol. 17, N 2. P. 85–93. DOI: https://doi.org/10.1111/j.1399-3038.­2005.00366.x
    15. Ellwood P., Asher M.I., García-Marcos L., Williams H., Keil U., Rober­t­son C., Nagel G.; ISAAC Phase III Study Group. Do fast foods cause asthma, rhinoconjunctivitis and eczema? Global findings from the International Study of Asthma and Allergies in Childhood (ISAAC) phase three // Thorax. 2013. Vol. 68, N 4. P. 351–360. DOI: https://doi.org/10.1136/thoraxjnl-2012-202285
    16. McNally N., Phillips D. Social factors and atopic dermatitis // Atopic dermatitis / H.C. Williams, editor. Cambridge: Cambridge University Press; 2000. P. 139–147.
    17. Strachan D.P. Hay fever, hygiene, and household size // BMJ. 1989. Vol. 299, N 6710. P. 1259–1260. DOI: https://doi.org/10.1136/bmj.299.6710.1259
    18. Proksch E., Brandner J.M., Jensen J.M. The skin: an indispensable barrier // Exp. Dermatol. 2008. Vol. 17, N 12. P. 1063–1072. DOI: https://doi.org/10.1111/j.1600-0625.2008.00786.x
    19. Gutowska-Owsiak D., de La Serna J.B., Fritzsche M., Naeem A., Podobas E.I., Leeming M., Colin-York H., O’Shaughnessy R, Egge­ling C., Ogg G.S. Orchestrated control of filaggrin-actin scaffolds underpins cornification // Cell Death Dis. 2018. Vol. 9, N 4. P. 412. DOI: https://doi.org/10.1038/s41419-018-0407-2
    20. Свирщевская Е.В., Матушевская Е.В. Роль липидов в барьер­ных свойствах кожи // Клиническая дерматология и венероло­гия. 2019. Т. 18, № 3. С. 360–365. DOI: https://doi.org/10.17116/klinderma201918031360
    21. Kizawa K., Takahara H., Unno M., Heizmann C.W. S100 and S100 fused-type protein families in epidermal maturation with special focus on S100A3 in mammalian hair cuticles // Biochimie. 2011. Vol. 93, N 12. P. 2038–2047. DOI: https://doi.org/10.1016/j.biochi.2011.05.028
    22. Elias P.M., Schmuth M. Abnormal skin barrier in the etiopathoge­nesis of atopic dermatitis // Curr. Allergy Asthma Rep. 2009. Vol. 9, N 4. P. 265–272. DOI: https://doi.org/10.1007/s11882-009-0037-y
    23. McAleer M.A., Irvine A.D. The multifunctional role of filaggrin in allergic skin disease // J. Allergy Clin. Immunol. 2013. Vol. 131, N 2. P. 280–291. DOI: https://doi.org/10.1016/j.jaci.2012.12.668
    24. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A. et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis // Nat. Genet. 2006. Vol. 38, N 4. P. 441–446. DOI: https://doi.org/10.1038/ng1767
    25. Scharschmidt T.C., Man M.Q., Hatano Y., Crumrine D., Gunathilake R., Sundberg J.P., Silva K.A., Mauro T.M., Hupe M., Cho S., Wu Y., Celli A., Schmuth M., Feingold K.R., Elias P.M. Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thre­sholds to irritants and haptens // J. Allergy Clin. Immunol. 2009. Vol. 124, N 3. P. 496–506, 506.e1–6. DOI: https://doi.org/10.1016/j.jaci.2009.06.046
    26. Eaaswarkhanth M., Xu D., Flanagan C., Rzhetskaya M., Hayes M.G., Blekhman R., Jablonski N.G., Gokcumen O. Atopic dermatitis susceptibility variants in filaggrin hitchhike hornerin selective sweep // Genome Biol. Evol. 2016. Vol. 8, N 10. P. 3240–3255. DOI: https://doi.org/10.1093/gbe/evw242
    27. Thawer-Esmail F., Jakasa I., Todd G. et al. South African amaXhosa patients with atopic dermatitis have decreased levels of filaggrin breakdown products but no loss-of-function mutations in filaggrin // J. Allergy Clin. Immunol. 2014. Vol. 133, N 1. P. 280–282.e1–2. DOI: https://doi.org/10.1016/j.jaci.2013.09.053
    28. Margolis D.J., Gupta J., Apter A.J., Ganguly T., Hoffstad O., Papa­dopoulos M., Rebbeck T.R., Mitra N. Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects // J. Allergy Clin. Immunol. 2014. Vol. 133, N 3. P. 784–789. DOI: https://doi.org/10.1016/j.jaci.2013.09.015
    29. Hertz A., Azulay-Abulafia L., Nascimento A.P.D., Ohara C.Y., Kusch­­nir F.C., Porto L.C. Analysis of filaggrin 2 gene polymorphisms in patients with atopic dermatitis // An. Bras. Dermatol. 2020. Vol. 95, N 2. P. 173–179. DOI: https://doi.org/10.1016/j.abd.2019.07.002
    30. Henry J., Hsu C.Y., Haftek M., Nachat R., de Koning H.D., Gardinal-Galera I., Hitomi K., Balica S., Jean-Decoster C., Schmitt A.M., Paul C., Serre G., Simon M. Hornerin is a component of the epidermal cornified cell envelopes // FASEB J. 2011. Vol. 25, N 5. P. 1567–1576. DOI: https://doi.org/10.1096/fj.10-168658
    31. Rahrig S., Dettmann J.M., Brauns B., Lorenz V.N., Buhl T., Kezic S., Elias P.M., Weidinger S., Mempel M., Schön M.P., Braun A. Transient epidermal barrier deficiency and lowered allergic threshold in filaggrin-hornerin (FlgHrnr-/-) double-deficient mice // Allergy. 2019. Vol. 74, N 7. P. 1327–1339. DOI: https://doi.org/10.1111/all.13756
    32. O’Regan G.M., Campbell L.E., Cordell H.J. et al. Chromosome 11q13.5 variant associated with childhood eczema: an effect supplemen­tary to filaggrin mutations // J. Allergy Clin. Immunol. 2010. Vol. 125, N 1. P. 170–174.e1–2. DOI: https://doi.org/10.1016/j.jaci.2009.10.046
    33. Trzeciak M., Wesserling M., Bandurski T., Glen J., Nowicki R., Pawelczyk T. Association of a single nucleotide polymorphism in a Late cornified Envelope-Like Proline-rich 1 gene (LELP1) with ato­pic dermatitis // Acta Derm. Venereol. 2016. Vol. 96. P. 459–463. DOI: https://doi.org/10.2340/00015555-2301
    34. Kato A., Fukai K., Oiso N., Hosomi N., Murakami T., Ishii M. Asso­ciation of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population // Br. J. Dermatol. 2003. Vol. 148, N 4. P. 665–669. DOI: https://doi.org/10.1046/j.1365-2133.2003. 05243.x
    35. Walley A.J., Chavanas S., Moffatt M.F., Esnouf R.M., Ubhi B., Lawrence R., Wong K., Abecasis G.R., Jones E.Y., Harper J.I., Hov­na­nian A., Cookson W.O. Gene polymorphism in Netherton and common atopic disease // Nat. Genet. 2001. Vol. 29, N 2. P. 175–178. DOI: https://doi.org/10.1038/ng728
    36. Martin M.J., Estravís M., García-Sánchez A., Dávila I., Isidoro-García M., Sanz C. Genetics and Epigenetics of Atopic Dermatitis: An Updated Systematic Review // Genes. 2020. Vol. 11. P. 442. DOI: https://doi.org/10.3390/genes11040442
    37. Yu H.S., Kang M.J., Kwon J.W., Lee S.Y., Lee E., Yang S.I., Jung Y.H., Hong K., Kim Y.J., Lee S.H., Kim H.J., Kim H.Y., Seo J.H., Kim B.J., Kim H.B., Hong S.J. Claudin-1 polymorphism modifies the effect of mold exposure on the development of atopic dermatitis and pro­duction of IgE // J. Allergy Clin. Immunol. 2015. Vol. 135, N 3. P. 827–830.e5. DOI: https://doi.org/10.1016/j.jaci.2014.10.040
    38. Weidinger S., Willis-Owen S.A., Kamatani Y. et al. A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis // Hum. Mol. Genet. 2013. Vol. 22, N 23. P. 4841–4856. DOI: https://doi.org/10.1093/hmg/ddt317
    39. Shen C., Liu L., Jiang Z., Zheng X., Meng L., Yin X., Gao J., Sheng Y., Gao J., Li Y., Zhou F., Xiao F., Sun L., Cui Y., Yang S., Zuo X., Zhang X. Four genetic variants interact to confer susceptibility to atopic dermatitis in Chinese Han population // Mol. Genet. Genomics. 2015. Vol. 290, N 4. P. 1493–1498. DOI: https://doi.org/10.1007/s00438-015-1014-x
    40. Hirota T., Takahashi A., Kubo M., Tsunoda T., Tomita K., Sakashita M., Yamada T., Fujieda S., Tanaka S., Doi S., Miyatake A., Enomoto T., Nishiyama C., Nakano N., Maeda K., Okumura K., Ogawa H., Ikeda S., Noguchi E., Sakamoto T., Hizawa N., Ebe K., Saeki H., Sasaki T., Ebihara T., Amagai M., Takeuchi S., Furue M., Nakamura Y., Tamari M. Genome-wide association study identifies eight new suscep­tibility loci for atopic dermatitis in the Japanese population // Nat. Genet. 2012. Vol. 44, N 11. P. 1222–1226. DOI: https://doi.org/10.1038/ng.2438
    41. Kang Z., Li Q., Fu P., Yan S., Guan M., Xu J., Xu F. Correlation of KIF3A and OVOL1, but not ACTL9, with atopic dermatitis in Chinese pe­diatric patients // Gene. 2015. Vol. 571, N 2. P. 249–251. DOI: https://doi.org/10.1016/j.gene.2015.06.068
    42. Ozceker D., Yucel E., Sipahi S., Dilek F., Ozkaya E., Guler E.M., Kocyi­git A., Guler N., Tamay Z. Evaluation of periostin level for pre­dicting severity and chronicity of childhood atopic dermatitis // Postepy Derma­tol. Alergol. 2019. Vol. 36, N 5. P. 616–619. DOI: https://doi.org/10.5114/ada.2018.79728
    43. Valcourt U., Alcaraz L.B., Exposito J.Y., Lethias C., Bartholin L. Tenascin-X: beyond the architectural function // Cell. Adh. Migr. 2015. Vol. 9, N 1–2. P. 154–165. DOI: https://doi.org/10.4161/19336918.2014.994893
    44. Lee H.J., Ha S.J., Han H., Kim J.W. Distribution of HLA-A, B alleles and polymorphisms of TAP and LMP genes in Korean patients with atopic dermatitis // Clin. Exp. Allergy. 2001. Vol. 31, N 12. P. 1867–1874. DOI: https://doi.org/10.1046/j.1365-2222.2001.01042.x
    45. Al-Shobaili H.A., Ahmed A.A., Alnomair N., Alobead Z.A., Rasheed Z. Molecular Genetic of Atopic dermatitis: An Update // Int. J. Health Sci. (Qassim). 2016. Vol. 10, N 1. P. 96–120.
    46. Margolis D.J., Mitra N., Kim B.S., Duke J.L., Berna R.A., Hoffstad O.J., Wasserman J.R., Ferriola D.A., Mosbruger T.L., Wubbenhorst B.S., Nathanson K.L., Monos D.S. HLA class I polymorphisms influen­cing both peptide binding and kir interactions are associated with re­mission among children with atopic dermatitis: a longitudinal study // J. Immunol. 2021. Vol. 206, N 9. P. 2038–2044. DOI: https://doi.org/10.4049/jimmunol.2001252
    47. Niepiekło-Miniewska W., Mpakali A., Stratikos E., Matusiak Ł., Narbutt J., Lesiak A., Kuna P., Wilczyńska K., Nowak I., Wiśniewski A., Zwolińska K., Ponińska J., Płoski R., Szepietowski J.C., Kuśnier­­­czyk P. Endoplasmic reticulum aminopeptidase 1 polymorphism Ile276Met is associated with atopic dermatitis and affects the generation of an HLA-C associated antigenic epitope in vitro // J. Eur. Acad. Dermatol. Venereol. 2019. Vol. 33, N 5. P. 906–911. DOI: https://doi.org/10.1111/jdv.15449
    48. Quiñones-Lombraña A., Lopez-Soto A., Ballina-Garcia F.J., Alperi-López M., Queiro-Silva R., Lopez-Vazquez A., Lopez-Larrea C., Gonzalez S. BAT1 promoter polymorphism is associated with rheumatoid arthritis susceptibility // J. Rheumatol. 2008. Vol. 35, N 5. P. 741–744.
    49. Allcock R.J., Williams J.H., Price P. The central MHC gene, BAT1, may encode a protein that down-regulates cytokine production // Genes Cells. 2001. Vol. 6, N 5. P. 487–494. DOI: https://doi.org/10.1046/j.1365-2443.2001.00435.x
    50. Kerr J.R., Kaushik N., Fear D., Baldwin D.A., Nuwaysir E.F., Ad­cock I.M. Single-nucleotide polymorphisms associated with sympto­matic infection and differential human gene expression in healthy sero­positive persons each implicate the cytoskeleton, integrin signaling, and oncosuppression in the pathogenesis of human par­vovirus B19 infection // J. Infect. Dis. 2005. Vol. 192, N 2. P. 276–286. DOI: https://doi.org/10.1086/430950
    51. Le Clerc S., Coulonges C., Delaneau O. et al. Screening low-frequency SNPS from genome-wide association study reveals a new risk allele for progression to AIDS // J. Acquir. Immune Defic. Syndr. 2011. Vol. 56, N 3. P. 279–284. DOI: https://doi.org/10.1097/QAI.0b013e318204982b
    52. Taylor R.S., Baadsgaard O., Hammerberg C., Cooper K.D. Hyper­stimulatory CD1a+CD1b+CD36+ Langerhans cells are responsible for increased autologous T lymphocyte reactivity to lesional epidermal cells of patients with atopic dermatitis // J. Immunol. 1991. Vol. 147, N 11. P. 3794–3802.
    53. Azcutia V., Stefanidakis M., Tsuboi N. et al. Endothelial CD47 promotes vascular endothelial-cadherin tyrosine phosphorylation and participates in T cell recruitment at sites of inflammation in vivo // J. Immunol. 2012. Vol. 189, N 5. P. 2553–2562. doi:10.4049/jimmunol.1103606.
    54. Looman K.I.M., van Meel E.R., Grosserichter-Wagener C. et al. As­so­ciations of Th2, Th17, Treg cells, and IgA+ memory B cells with atopic disease in children: The Generation R Study // Allergy. 2020. Vol. 75, N 1. P. 178–187. DOI: https://doi.org/10.1111/all.14010
    55. Lee N., Shin J.U., Jin S., Yun K.N., Kim J.Y., Park C.O., Kim S.H., Noh J.Y., Lee K.H. Upregulation of CD47 in regulatory T cells in atopic dermatitis // Yonsei Med. J. 2016. Vol. 57, N 6. P. 1435–1445. DOI: https://doi.org/10.3349/ymj.2016.57.6.1435
    56. Murphy-Ullrich J.E., Suto M.J. Thrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease // Matrix Biol. 2018. Vol. 68–69. P. 28–43. DOI: https://doi.org/10.1016/j.matbio.2017.12.009
    57. Puxeddu I., Rabl S.C., Panza F., Pratesi F., Rocchi V., Del Corso I., Migliorini P. Endostatin and Thrombospondin-1 levels are increased in the sera of patients with chronic spontaneous urticaria // Arch. Dermatol. Res. 2014. Vol. 306, N 2. P. 197–200. DOI: https://doi.org/10.1007/s00403-013-1405-y
    58. Li X., Howard T.D., Zheng S.L., Haselkorn T., Peters S.P., Meyers D.A., Bleecker E.R. Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions // J. Allergy Clin. Immunol. 2010. Vol. 125, N 2. P. 328–335.e11. DOI: https://doi.org/10.1016/j.jaci.2009.11.018
    59. Bivik C., Verma D., Winge M.C., Lieden A., Bradley M., Rosdahl I., Söderkvist P. Genetic variation in the inflammasome and atopic dermatitis susceptibility // J. Invest. Dermatol. 2013. Vol. 133, N 10. P. 2486–2489. DOI: https://doi.org/10.1038/jid.2013.168
    60. Furue K., Ito T., Tsuji G., Ulzii D., Vu Y.H., Kido-Nakahara M., Nakahara T., Furue M. The IL-13-OVOL1-FLG axis in atopic dermatitis // Immunology. 2019. Vol. 158, N 4. P. 281–286. DOI: https://doi.org/10.1111/imm.13120
    61. Wilson S.R., Thé L., Batia L.M. et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch // Cell. 2013. Vol. 155, N 2. P. 285–295. DOI: https://doi.org/10.1016/j.cell.2013.08.057
    62. Di L., Cheng D., Zhang K. et al. Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitis // Mucosal Immunol. 2017. Vol. 10, N 6. P. 1491–1503. DOI: https://doi.org/10.1038/mi.2017.10
    63. Esparza-Gordillo J., Weidinger S., Fölster-Holst R., Bauerfeind A., Ruschendorf F., Patone G., Rohde K., Marenholz I., Schulz F., Kerscher T., Hubner N., Wahn U., Schreiber S., Franke A., Vogler R., Heath S., Baurecht H., Novak N., Rodriguez E., Illig T., Lee-Kirsch M.A., Ciechanowicz A., Kurek M., Piskackova T., Macek M., Lee Y.A., Ruether A. A common variant on chromosome 11q13 is associated with atopic dermatitis // Nat. Genet. 2009. Vol. 41, N 5. P. 596–601. DOI: https://doi.org/10.1038/ng.347
    64. Greisenegger E.K., Zimprich F., Zimprich A., Gleiss A., Kopp T. Association of the chromosome 11q13.5 variant with atopic dermatitis in Austrian patients // Eur J Dermatol. 2013. Vol. 23, N 2. P. 142–145. DOI: https://doi.org/10.1684/ejd.2013.1955
    65. Ponińska J.K., Samoliński B., Tomaszewska A., Raciborski F., Samel-Kowalik P., Walkiewicz A., Lipiec A., Piekarska B., Krzych-Fałta E., Namysłowski A., Kostrzewa G., Pawlik A., Jasek M., Wiśniewski A., Kuśnierczyk P., Majewski S., Płoski R. Haplotype dependent association of rs7927894 (11q13.5) with atopic dermatitis and chronic allergic rhinitis: A study in ECAP cohort // PLoS One. 2017. Vol. 12, N 9. Article ID e0183922. DOI: https://doi.org/10.1371/journal.pone.0183922
    66. Elias M.S., Wright S.C., Remenyi J., Abbott J.C. et al. EMSY expression affects multiple components of the skin barrier with relevance to atopic dermatitis // J. Allergy Clin. Immunol. 2019. Vol. 144, N 2. P. 470–481. DOI: https://doi.org/10.1016/j.jaci.2019.05.024
    67. Gauthy E., Cuende J., Stockis J., Huygens C., Lethé B., Collet J.F., Bommer G., Coulie P.G., Lucas S. GARP is regulated by miRNAs and controls latent TGF-β1 production by human regulatory T cells // PLoS One. 2013. Vol. 8, N 9. Article ID e76186. DOI: https://doi.org/10.1371/journal.pone.0076186
    68. Manz J., Rodríguez E., ElSharawy A., Oesau E.M., Petersen B.S., Baurecht H., Mayr G., Weber S., Harder J., Reischl E., Schwarz A., Novak N., Franke A., Weidinger S. Targeted resequencing and fun­ctional testing identifies low-frequency missense variants in the gene encoding garp as significant contributors to atopic dermatitis risk // J. Invest. Dermatol. 2016. Vol. 136, N 12. P. 2380–2386. DOI: https://doi.org/10.1016/j.jid.2016.07.009
    69. Danso M.O., van Drongelen V., Mulder A., van Esch J., Scott H., van Smeden J., El Ghalbzouri A., Bouwstra J.A. TNF-α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents // J. Invest. Dermatol. 2014. Vol. 134, N 7. P. 1941–1950. DOI: https://doi.org/10.1038/jid.2014.83
    70. Jacobi A., Antoni C., Manger B., Schuler G., Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis // J. Am. Acad. Dermatol. 2005. Vol. 52, N 3. Pt 1. P. 522–526. DOI: https://doi.org/10.1016/j.jaad.2004.11.022
    71. Sääf A., Pivarcsi A., Winge M.C., Wahlgren C.F., Homey B., Nor­denskjöld M., Tengvall-Linder M., Bradley M. Characterization of EGFR and ErbB2 expression in atopic dermatitis patients // Arch. Dermatol. Res. 2012. Vol. 304, N 10. P. 773–780. DOI: https://doi.org/10.1007/s00403-012-1242-4
    72. Thomsen S.F., Ulrik C.S., Kyvik K.O., Hjelmborg Jv., Skadhauge L.R., Steffensen I., Backer V. Importance of genetic factors in the etiology of atopic dermatitis: a twin study // Allergy Asthma Proc. 2007. Vol. 28, N 5. P. 535–539. DOI: https://doi.org/10.2500/aap2007.28.3041
    73. Johansson E., Biagini Myers J.M., Martin L.J. et al. Identification of two early life eczema and non-eczema phenotypes with high risk for asthma development // Clin. Exp. Allergy. 2019. Vol. 49, N 6. P. 829–837. DOI: https://doi.org/10.1111/cea.13379
    74. Ramesh K., Matta S.A., Chew F.T., Mok Y.K. Exonic mutations associated with atopic dermatitis disrupt lympho-epithelial Kazal-type related inhibitor action and enhance its degradation // Allergy. 2020. Vol. 75, N 2. P. 403–411. DOI: https://doi.org/10.1111/all.14018
    75. Marenholz I., Rivera V.A., Esparza-Gordillo J., Bauerfeind A., Lee-Kirsch M.A., Ciechanowicz A., Kurek M., Piskackova T., Macek M., Lee Y.A. Association screening in the Epidermal Differentiation Complex (EDC) identifies an SPRR3 repeat number variant as a risk factor for eczema // J. Invest. Dermatol. 2011. Vol. 131, N 8. P. 1644–1649. DOI: https://doi.org/10.1038/jid.2011.90
    76. Liang Y., Chang C., Lu Q. The genetics and epigenetics of atopic dermatitis-filaggrin and other polymorphisms // Clin. Rev. Al­lergy Immunol. 2016. Vol. 51, N 3. P. 315–328. DOI: https://doi.org/10.1007/s12016-015-8508-5
    77. Weidinger S., Novak N. Atopic dermatitis // Lancet. 2016. Vol. 387, N 10023. P. 1109–1122. DOI: https://doi.org/10.1016/S0140-6736(15)00149-X
    78. Eichenfield L.F., Tom W.L., Chamlin S.L. et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and as­sessment of atopic dermatitis // J. Am. Acad. Dermatol. 2014. Vol. 70, N 2. P. 338–351. DOI: https://doi.org/10.1016/j.jaad.2013.10.010
    79. Maliyar K., Sibbald C., Pope E., Gary Sibbald R. Diagnosis and ma­nagement of atopic dermatitis: a review // Adv. Skin Wound Care. 2018. Vol. 31, N 12. P. 538–550. DOI: https://doi.org/10.1097/01.ASW.0000547414.38888.8d
    80. Torres T., Ferreira E.O., Gonçalo M., Mendes-Bastos P., Selores M., Filipe P. Update on atopic dermatitis // Acta Med. Port. 2019. Vol. 32, N 9. P. 606–613. DOI: https://doi.org/10.20344/amp.11963
    81. Strathie Page S., Weston S., Loh R. Atopic dermatitis in children // Aust. Fam. Physician. 2016. Vol. 45, N 5. P. 293–296.
    82. Tay Y.K., Chan Y.C., Chandran N.S., Ho M.S., Koh M.J., Lim Y.L., Tang M.B., Thirumoorthy T. Guidelines for the management of atopic dermatitis in Singapore // Ann. Acad. Med. Singap. 2016. Vol. 45, N 10. P. 439–450.
    83. Katoh N., Ohya Y., Ikeda M., Ebihara T., Katayama I., Saeki H., Shimojo N., Tanaka A., Nakahara T., Nagao M., Hide M., Fujita Y., Fujisawa T., Futamura M., Masuda K., Murota H., Yamamoto-Hanada K. Clinical practice guidelines for the management of atopic dermatitis 2018 // J. Dermatol. 2019. Vol. 46, N 12. P. 1053–1101. DOI: https://doi.org/10.1111/1346-8138.15090
    84. Katayama I., Aihara M., Ohya Y., Saeki H., Shimojo N., Shoji S., Taniguchi M., Yamada H.; Japanese Society of Allergology. Japanese guidelines for atopic dermatitis 2017 // Allergol. Int. 2017. Vol. 66, N 2. P. 230–247. DOI: https://doi.org/10.1016/j.alit.2016.12.003
    85. Brar K.K., Nicol N.H., Boguniewicz M. Strategies for Successful Management of Severe Atopic Dermatitis // J. Allergy Clin. Immunol. Pract. 2019. Vol. 7, N 1. P. 1–16. DOI: https://doi.org/10.1016/j.jaip.2018.10.021
    86. Gelmetti C. Extracutaneous manifestations of atopic dermatitis // Pediatr. Dermatol. 1992. Vol. 9, N 4. P. 380–382. DOI: https://doi.org/10.1111/j.1525-1470.1992.tb00637.x
    87. Thyssen J.P., Godoy-Gijon E., Elias P.M. Ichthyosis vulgaris: the filaggrin mutation disease // Br. J. Dermatol. 2013. Vol. 168, N 6. P. 1155–1166. DOI: https://doi.org/10.1111/bjd.12219
    88. Nicholas M.N., Gooderham M.J. Atopic dermatitis, depression, and suicidality // J. Cutan. Med. Surg. 2017. Vol. 21, N 3. P. 237–242. DOI: https://doi.org/10.1177/1203475416685078
    89. Chamlin S.L., Frieden I.J., Williams M.L., Chren M.M. Effects of atopic dermatitis on young American children and their families // Pediatrics. 2004. Vol. 114, N 3. P. 607–611. DOI: https://doi.org/10.1542/peds.2004-0374
    90. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis // Dermatology. 1993. Vol. 186, N 1. P. 23–31. DOI: https://doi.org/10.1159/000247298
    91. Schmitt J., Williams H.; HOME Development Group. Harmonising Outcome Measures for Eczema (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany // Br. J. Dermatol. 2010. Vol. 163, N 6. P. 1166–1168. DOI: https://doi.org/10.1111/j.1365-2133.2010.10054.x
    92. Guttman-Yassky E., Blauvelt A., Eichenfield L.F., Paller A.S., Arm­strong A.W., Drew J., Gopalan R., Simpson E.L. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial // JAMA Dermatol. 2020. Vol. 156, N 4. P. 411–420. DOI: https://doi.org/10.1001/jamadermatol.2020.0079
    93. Simpson E.L., Bieber T., Guttman-Yassky E., Beck L.A. et al.; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis // N. Engl. J. Med. 2016. Vol. 375, N 24. P. 2335–2348. DOI: https://doi.org/10.1056/NEJMoa1610020
    94. Wollenberg A., Howell M.D., Guttman-Yassky E., Silverberg J.I., Kell C., Ranade K., Moate R., van der Merwe R. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb // J. Allergy Clin. Immunol. 2019. Vol. 143, N 1. P. 135–141. DOI: https://doi.org/10.1016/j.jaci.2018.05.029
    1. Guttman-Yassky E., Thaçi D., Pangan A.L., Hong H.C., Papp K.A., Reich K., Beck L.A., Mohamed M.F., Othman A.A., Anderson J.K., Gu Y., Teixeira H.D., Silverberg J.I. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial // J. Allergy Clin. Immunol. 2020. Vol. 145, N 3. P. 877–884. DOI: https://doi.org/10.1016/j.jaci.2019.11.025
    2. Gooderham M.J., Forman S.B., Bissonnette R., Beebe J.S., Zhang W., Banfield C., Zhu L., Papacharalambous J., Vincent M.S., Pe­eva E. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial // JAMA Dermatol. 2019. Vol. 155, N 12. P. 1371–1379. DOI: https://doi.org/10.1001/jamadermatol.2019.2855 (Erratum in: JAMA Dermatol. 2020. Vol. 156, N 1. P. 104.)
    3. Reich K., Kabashima K., Peris K. et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial // JAMA Dermatol. 2020. Vol. 156, N 12. P. 1333–1343. DOI: https://doi.org/10.1001/jamadermatol.2020.3260
    4. Kabashima K., Matsumura T., Komazaki H., Kawashima M.; Ne­molizumab-JP01 Study Group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus // N. Engl. J. Med. 2020. Vol. 383, N 2. P. 141–150. DOI: https://doi.org/10.1056/NEJMoa1917006
    5. Simpson E.L., Parnes J.R., She D., Crouch S., Rees W., Mo M., van der Merwe R. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial // J. Am. Acad. Dermatol. 2019. Vol. 80, N 4. P. 1013–1021. DOI: https://doi.org/10.1016/j.jaad.2018.11.059
    6. Коновалова М.В., Зубарева А.А., Луценко Г.В., Свирщевс­кая Е.В. Антимикробные пептиды в норме и при патологиях // Прикладная биохимия и микробиология. 2018. Vol. 54, 3. P. 236–243. DOI: https://doi.org/10.7868/S0555109918030029
    7. Wollenberg A., Räwer H.C., Schauber J. Innate immunity in atopic dermatitis // Clin. Rev. Allergy Immunol. 2011. Vol. 41, N 3. P. 272–281. DOI: https://doi.org/10.1007/s12016-010-8227-x
    8. Nguyen H.L.T., Trujillo-Paez J.V., Umehara Y., Yue H., Peng G., Kiatsurayanon C., Chieosilapatham P., Song P., Okumura K., Oga­wa H., Ikeda S., Niyonsaba F. Role of antimicrobial peptides in skin bar­rier repair in individuals with atopic dermatitis // Int. J. Mol. Sci. 2020. Vol. 21, N 20. P. 7607. DOI: https://doi.org/10.3390/ijms21207607
    9. Tominaga M., Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications // J. Dermatol. 2014. Vol. 41, N 3. P. 205–212. DOI: https://doi.org/10.1111/1346-8138.12317
    10. Wadhwa B., Relhan V., Goel K., Kochhar A.M., Garg V.K. Vitamin D and skin diseases: A review // Indian J. Dermatol. Venereol. Leprol. 2015. Vol. 81, N 4. P. 344–355. DOI: https://doi.org/10.4103/0378-6323.159928
    11. Schauber J., Dorschner R.A., Coda A.B., Büchau A.S., Liu P.T., Ki­ken D., Helfrich Y.R., Kang S., Elalieh H.Z., Steinmeyer A., Zügel U., Bikle D.D., Modlin R.L., Gallo R.L. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism // J. Clin. Invest. 2007. Vol. 117, N 3. P. 803–811. DOI: https://doi.org/10.1172/JCI30142
    12. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., Ochoa M.T., Schauber J., Wu K., Meinken C., Kamen D.L., Wagner M., Bals R., Steinmeyer A., Zügel U., Gallo R.L., Eisenberg D., Hewison M., Hollis B.W., Adams J.S., Bloom B.R., Modlin R.L. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response // Science. 2006. Vol. 311, N 5768. P. 1770–1773. DOI: https://doi.org/10.1126/science.1123933
    13. Honda T., Kabashima K. Reconciling innate and acquired immu­ni­ty in atopic dermatitis // J. Allergy Clin. Immunol. 2020. Vol. 145, N 4. P. 1136–1137. DOI: https://doi.org/10.1016/j.jaci.2020.02.008
    14. Nouwen A.E.M., Karadavut D., Pasmans S.G.M.A. et al. Natural moisturizing factor as a clinical marker in atopic dermatitis // Allergy. 2020. Vol. 75, N 1. P. 188–190. DOI: https://doi.org/10.1111/all.13942
    15. Danby S.G., Cork M.J. pH in atopic dermatitis // Curr. Probl. Derma­tol. 2018. Vol. 54. P. 95–107. DOI: https://doi.org/10.1159/000489523
    16. Yang G., Seok J.K., Kang H.C., Cho Y.Y., Lee H.S., Lee J.Y. Skin barrier abnormalities and immune dysfunction in atopic dermatitis // Int. J. Mol. Sci. 2020. Vol. 21, N 8. P. 2867. DOI: https://doi.org/10.3390/ijms21082867
    17. Hatano Y., Elias P.M., Crumrine D., Feingold K.R., Katagiri K., Fujiwara S. Efficacy of combined peroxisome proliferator-acti­vated receptor-α ligand and glucocorticoid therapy in a murine model of atopic dermatitis // J. Invest. Dermatol. 2011. Vol. 131, N 9. P. 1845–1852. DOI: https://doi.org/10.1038/jid.2011.144
    18. Sun L., Liu W., Zhang L.J. The Role of Toll-Like Receptors in Skin Host Defense, Psoriasis, and Atopic Dermatitis // J. Im­mu­nol. Res. 2019. Vol. 2019. P. 1824624. DOI: https://doi.org/10.1155/2019/1824624
    19. Skabytska Y., Kaesler S., Volz T., Biedermann T. How the innate immune system trains immunity: lessons from studying atopic dermatitis and cutaneous bacteria // J. Dtsch Dermatol. Ges. 2016. Vol. 14, N 2. P. 153–156. DOI: https://doi.org/10.1111/ddg.12843
    20. Zhang Y., Wang H.C., Feng C., Yan M. Analysis of the association of polymorphisms rs5743708 in TLR2 and rs4986790 in TLR4 with atopic dermatitis risk // Immunol. Invest. 2019. Vol. 48, N 2. P. 169–180. DOI: https://doi.org/10.1080/08820139.2018.1508228
    21. Yamanaka K., Tanaka M., Tsutsui H. et al. Skin-specific cas­pase-1-transgenic mice show cutaneous apoptosis and pre-endotoxin shock condition with a high serum level of IL-18 // J. Immunol. 2000. Vol. 165. P. 997–1003. DOI: https://doi.org/10.4049/jimmunol.165.2.997
    22. Cayrol C., Girard J.P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1 // Proc. Natl. Acad. Sci. USA. 2009. Vol. 106. P. 9021–9026. DOI: https://doi.org/10.1073/pnas.0812690106
    23. Ebner S., Nguyen V.A., Forstner M., Wang Y.H., Wolfram D., Liu Y.J., Romani N. Thymic stromal lymphopoietin converts human epi­der­mal Langerhans cells into antigen-presenting cells that induce proallergic T cells // J. Allergy Clin. Immunol. 2007. Vol. 119, N 4. P. 982–990. DOI: https://doi.org/10.1016/j.jaci.2007.01.003
    24. Salimi M., Barlow J.L., Saunders S.P. et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis // J. Exp. Med. 2013. Vol. 210, N 13. P. 2939–2950. DOI: https://doi.org/10.1084/jem.20130351
    25. Egert M., Simmering R. The microbiota of the human skin // Adv. Exp. Med. Biol. 2016. Vol. 902. P. 61–81. DOI: https://doi.org/10.1007/978-3-319-31248-4_5
    26. Bäckhed F., Roswall J., Peng Y., Feng Q., Jia H., Kovatcheva-Datchary P., Li Y., Xia Y., Xie H., Zhong H., Khan M.T., Zhang J., Li J., Xiao L., Al-Aama J., Zhang D., Lee Y.S., Kotowska D., Colding C., Tremaroli V., Yin Y., Bergman S., Xu X., Madsen L., Kristiansen K., Dahlgren J., Wang J. Dynamics and stabilization of the human gut microbiome during the first year of life // Cell Host Microbe. 2015. Vol. 17, N 5. P. 690–703. DOI: https://doi.org/10.1016/j.chom.2015.04.004 (Erratum in: Cell Host. Microbe. 2015. Vol. 17, N 6. P. 852.)
    27. Byrd A.L., Belkaid Y., Segre J.A. The human skin microbiome // Nat. Rev. Microbiol. 2018. Vol. 16, N 3. P. 143–155. DOI: https://doi.org/10.1038/nrmicro.2017.157
    28. Young V.B. The role of the microbiome in human health and disease: an introduction for clinicians // BMJ. 2017. Vol. 356. Article ID j831. DOI: https://doi.org/10.1136/bmj.j831
    29. Oh J., Conlan S., Polley E.C., Segre J.A., Kong H.H. Shifts in hu­man skin and nares microbiota of healthy children and adults // Ge­nome Med. 2012. Vol. 4, N 10. P. 77. DOI: https://doi.org/10.1186/gm378
    30. Nakamizo S., Egawa G., Honda T., Nakajima S., Belkaid Y., Ka­bashima K. Commensal bacteria and cutaneous immunity // Semin. Immunopathol. 2015. Vol. 37, N 1. P. 73–80. DOI: https://doi.org/10.1007/s00281-014-0452-6
    31. Kong H.H., Oh J., Deming C., Conlan S., Grice E.A., Beatson M.A., Nomicos E., Polley E.C., Komarow H.D.; NISC Comparative Sequence Program, Murray P.R., Turner M.L., Segre J.A. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis // Genome Res. 2012. Vol. 22, N 5. P. 850–859. DOI: https://doi.org/10.1101/gr.131029.111
    32. Seite S., Flores G.E., Henley J.B., Martin R., Zelenkova H., Agui­­­­lar L., Fierer N. Microbiome of affected and unaffected skin of pa­tients with atopic dermatitis before and after emollient treatment // J. Drugs Dermatol. 2014. Vol. 13, N 11. P. 1365–1372.
    33. Furue M., Ulzii D., Vu Y.H., Tsuji G., Kido-Nakahara M., Nakahara T. Pathogenesis of atopic dermatitis: current paradigm // Iran J. Immunol. 2019. Vol. 16, N 2. P. 97–107. DOI: https://doi.org/10.22034/IJI.2019.80253
    34. Zedan K., Rasheed Z., Farouk Y., Alzolibani A.A., Bin Saif G., Ismail H.A., Al Robaee A.A. Immunoglobulin e, interleukin-18 and inter­leukin-12 in patients with atopic dermatitis: correlation with di­sease activity // J. Clin. Diagn. Res. 2015. Vol. 9, N 4. Article ID WC01–5. DOI: https://doi.org/10.7860/JCDR/2015/12261.5742
    35. Kou K., Aihara M., Matsunaga T., Chen H., Taguri M., Morita S., Fujita H., Yamaguchi Y., Kambara T., Ikezawa Z. Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis // Arch. Dermatol. Res. 2012. Vol. 304, N 4. P. 305–312. DOI: https://doi.org/10.1007/s00403-011-1198-9
    36. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells // Nat. Immunol. 2009. Vol. 10, N 8. P. 857–863. DOI: https://doi.org/10.1038/ni.1767
    37. Sanyal R.D., Pavel A.B., Glickman J., Chan T.C., Zheng X., Zhang N., Cueto I., Peng X., Estrada Y., Fuentes-Duculan J., Alexis A.F., Krueger J.G., Guttman-Yassky E. Atopic dermatitis in African American patients is Th2/Th22-skewed with Th1/Th17 attenuation // Ann. Allergy Asthma Immunol. 2019. Vol. 122, N 1. P. 99–110.e6. DOI: https://doi.org/10.1016/j.anai.2018.08.024
    38. Pavel A.B., Zhou L., Diaz A., Ungar B., Dan J., He H., Estrada Y.D., Xu H., Fernandes M., Renert-Yuval Y., Krueger J.G., Guttman-Yassky E. The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature // J. Am. Acad. Dermatol. 2020. Vol. 82, N 3. P. 690–699. DOI: https://doi.org/10.1016/j.jaad.2019.10.039
    39. Roesner L.M., Floess S., Witte T., Olek S., Huehn J., Werfel T. Foxp3(+) regulatory T cells are expanded in severe atopic dermatitis patients // Allergy. 2015. Vol. 70, N 12. P. 1656–1660. DOI: https://doi.org/10.1111/all.12712
    40. Ma L., Xue H.B., Guan X.H., Shu C.M., Wang F., Zhang J.H., An R.Z. The Imbalance of Th17 cells and CD4(+) CD25(high) Foxp3(+) Treg cells in patients with atopic dermatitis // J. Eur. Acad. Dermatol. Venereol. 2014. Vol. 28, N 8. P. 1079–1086. DOI: https://doi.org/10.1111/jdv.12288
    41. Liu F.T., Goodarzi H., Chen H.Y. IgE, mast cells, and eosinophils in atopic dermatitis // Clin. Rev. Allergy Immunol. 2011. Vol. 41, N 3. P. 298–310. DOI: https://doi.org/10.1007/s12016-011-8252-4
    42. Yamamoto N., Sugiura H., Tanaka K., Uehara M. Heterogeneity of interleukin 5 genetic background in atopic dermatitis patients: signifi­cant difference between those with blood eosino­philia and normal eosinophil levels // J. Dermatol. Sci. 2003. Vol. 33, N 2. P. 121–126. DOI: https://doi.org/10.1016/s0923-1811(03)00149-x
    43. Schäfer T., Heinrich J., Wjst M., Adam H., Ring J., Wichmann H.E. Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren // J. Allergy Clin. Immunol. 1999. Vol. 104, N 6. P. 1280–1284. DOI: https://doi.org/10.1016/s0091-6749(99)70025-4
    44. Joishy M., Alfaham M., Tuthill D. Does the severity of atopic dermatitis correlate with serum IgE levels? // Pediatr. Allergy Immunol. 2005. Vol. 16, N 3. P. 283. DOI: https://doi.org/10.1111/j.1399-3038.2005.00212.x
    45. Laske N., Niggemann B. Does the severity of atopic dermatitis correlate with serum IgE levels? // Pediatr. Allergy Immunol. 2004. Vol. 15, N 1. P. 86–88. DOI: https://doi.org/10.1046/j.0905-6157.2003.00106.x
    46. Hill D.J., Hosking C.S. Food allergy and atopic dermatitis in infancy: an epidemiologic study // Pediatr. Allergy Immunol. 2004. Vol. 15, N 5. P. 421–427. DOI: https://doi.org/10.1111/j.1399-3038.2004.00178.x
    47. Hill D.J., Hosking C.S., de Benedictis F.M., Oranje A.P., Diepgen T.L., Bauchau V.; EPAAC Study Group. Confirmation of the association between high levels of immunoglobulin E food sensitization and eczema in infancy: an international study // Clin. Exp. Allergy. 2008. Vol. 38, N 1. P. 161–168. DOI: https://doi.org/10.1111/j.1365-2222.2007.02861.x
    48. Osterballe M., Mortz C.G., Hansen T.K., Andersen K.E., Bindslev-Jensen C. The prevalence of food hypersensitivity in young adults // Pediatr. Allergy Immunol. 2009. Vol. 20, N 7. P. 686–692. DOI: https://doi.org/10.1111/j.1399-3038.2008.00842.x
    49. Hauser C., Wuethrich B., Matter L., Wilhelm J.A., Schopfer K. Immune response to Staphylococcus aureus in atopic dermatitis // Dermatologica. 1985. Vol. 170, N 3. P. 114–120. DOI: https://doi.org/10.1159/000249514
    50. Fukushima H., Hirano T., Shibayama N., Miwa K., Ito T., Saito M., Sumida H., Oyake S., Tsuboi R., Oka K. The role of immune response to Staphylococcus aureus superantigens and disease severity in relation to the sensitivity to tacrolimus in atopic dermatitis // Int. Arch. Allergy Immunol. 2006. Vol. 141, N 3. P. 281–289. DOI: https://doi.org/10.1159/000095298
    51. Kabashima-Kubo R., Nakamura M., Sakabe J., Sugita K., Hino R., Mori T., Kobayashi M., Bito T., Kabashima K., Ogasawara K., Nomura Y., Nomura T., Akiyama M., Shimizu H., Tokura Y. A group of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: possible immunological state of the intrinsic type // J. Dermatol. Sci. 2012. Vol. 67, N 1. P. 37–43. DOI: https://doi.org/10.1016/j.jdermsci.2012.04.004
    52. Yamaguchi H., Kabashima-Kubo R., Bito T., Sakabe J., Shimauchi T., Ito T., Hirakawa S., Hirasawa N., Ogasawara K., Tokura Y. High frequencies of positive nickel/cobalt patch tests and high sweat nickel concentration in patients with intrinsic atopic dermatitis // J. Dermatol. Sci. 2013. Vol. 72, N 3. P. 240–245. DOI: https://doi.org/10.1016/j.jdermsci.2013.07.009
    53. Suárez-Fariñas M., Dhingra N., Gittler J., Shemer A., Cardinale I., de Guzman Strong C., Krueger J.G., Guttman-Yassky E. Intrinsic atopic dermatitis shows similar Th2 and higher Th17 immune activation compared with extrinsic atopic dermatitis // J. Allergy Clin. Immunol. 2013. Vol. 132, N 2. P. 361–370. DOI: https://doi.org/10.1016/j.jaci.2013.04.046
    54. Roguedas-Contios A.M., Misery L. What is intrinsic atopic dermatitis? // Clin. Rev. Allergy Immunol. 2011. Vol. 41, N 3. P. 233–236. DOI: https://doi.org/10.1007/s12016-011-8276-9
    55. Martel B.C., Litman T., Hald A., Norsgaard H., Lovato P., Dyring-Andersen B., Skov L., Thestrup-Pedersen K., Skov S., Skak K., Poulsen L.K. Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis // Exp. Dermatol. 2016. Vol. 25, N 6. P. 453–459. DOI: https://doi.org/10.1111/exd.12967
    56. Czarnowicki T., He H., Krueger J.G., Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics // J. Allergy Clin. Immunol. 2019. Vol. 143, N 1. P. 1–11. DOI: https://doi.org/10.1016/j.jaci.2018.10.032
    57. Ahlström M.G., Thyssen J.P., Wennervaldt M., Menné T., Johan­sen J.D. Nickel allergy and allergic contact dermatitis: A clinical review of immunology, epidemiology, exposure, and treatment // Contact Dermatitis. 2019. Vol. 81, N 4. P. 227–241. DOI: https://doi.org/10.1111/cod.13327
    58. Nomura T., Honda T., Kabashima K. Multipolarity of cytokine axes in the pathogenesis of atopic dermatitis in terms of age, race, species, disease stage and biomarkers // Int. Immunol. 2018. Vol. 30, N 9. P. 419–428. DOI: https://doi.org/10.1093/intimm/dxy015
    59. Garritsen F.M., ter Haar N.M., Spuls P.I. House dust mite reduc­tion in the management of atopic dermatitis. A critically appraised topic // Br. J. Dermatol. 2013. Vol. 168, N 4. P. 688–691. DOI: https://doi.org/10.1111/bjd.12283
    60. Herro E.M., Matiz C., Sullivan K., Hamann C., Jacob S.E. Frequency of contact allergens in pediatric patients with atopic dermatitis // J. Clin. Aesthet. Dermatol. 2011. Vol. 4, N 11. P. 39–41.
    61. Thyssen J.P., McFadden J.P., Kimber I. The multiple factors affecting the association between atopic dermatitis and contact sensitization // Allergy. 2014. Vol. 69, N 1. P. 28–36. DOI: https://doi.org/10.1111/all.12358
    62. Tham E.H., Rajakulendran M., Lee B.W., Van Bever H.P.S. Epicu­taneous sensitization to food allergens in atopic dermatitis: What do we know? // Pediatr. Allergy Immunol. 2020. Vol. 31, N 1. P. 7–18. DOI: https://doi.org/10.1111/pai.13127
    63. Lee J., Jang A., Seo S.J., Myung S.C. Epigenetic regulation of filaggrin gene expression in human epidermal keratinocytes // Ann. Dermatol. 2020. Vol. 32, N 2. P. 122–129. DOI: https://doi.org/10.5021/ad.2020.32.2.122
    64. Nedoszytko B., Reszka E., Gutowska-Owsiak D., Trzeciak M., Lan­ge M., Jarczak J., Niedoszytko M., Jablonska E., Romantowski J., Stra­pagiel D., Skokowski J., Siekierzycka A., Nowicki R.J., Dob­rucki I.T., Zaryczańska A., Kalinowski L. Genetic and Epige­netic Aspects of Atopic Dermatitis // Int. J. Mol. Sci. 2020. Vol. 21, N 18. P. 6484. DOI: https://doi.org/10.3390/ijms21186484
    65. Acevedo N., Benfeitas R., Katayama S., Bruhn S., Andersson A., Wik­berg G., Lundeberg L., Lindvall J.M., Greco D., Kere J., Sö­derhäll C., Scheynius A. Epigenetic alterations in skin homing CD4+CLA+ T cells of atopic dermatitis patients // Sci. Rep. 2020. Vol. 10, N 1. P. 18020. DOI: https://doi.org/10.1038/s41598-020-74798-z
    66. Ng Y.T., Chew F.T. A systematic review and meta-analysis of risk factors associated with atopic dermatitis in Asia // World Allergy Organ. J. 2020. Vol. 13, N 11. P. 100477. DOI: https://doi.org/10.1016/j.waojou.2020.100477
    67. Kantor R., Kim A., Thyssen J.P., Silverberg J.I. Association of atopic dermatitis with smoking: A systematic review and meta-analysis // J. Am. Acad. Dermatol. 2016. Vol. 75, N 6. P. 1119–1125.e1. DOI: https://doi.org/10.1016/j.jaad.2016.07.017
    68. Kim S.Y., Sim S., Choi H.G. Atopic dermatitis is associated with active and passive cigarette smoking in adolescents // PLoS One. 2017. Vol. 12, N 11. Article ID e0187453. DOI: https://doi.org/10.1371/journal.pone.0187453
    69. Schmidt M., Goebeler M. Nickel allergies: paying the Toll for innate immunity // J. Mol. Med. (Berl). 2011. Vol. 89, N 10. P. 961–970. DOI: https://doi.org/10.1007/s00109-011-0780-0
    70. Hamann C.R., Hamann D., Egeberg A., Johansen J.D., Silver­berg J., Thyssen J.P. Association between atopic dermatitis and con­tact sensitization: A systematic review and meta-analysis // J. Am. Acad. Dermatol. 2017. Vol. 77, N 1. P. 70–78. DOI: https://doi.org/10.1016/j.jaad.2017.02.001
    71. Kaplan D.H., Igyártó B.Z., Gaspari A.A. Early immune events in the induction of allergic contact dermatitis // Nat. Rev. Immunol. 2012. Vol. 12, N 2. P. 114–124. DOI: https://doi.org/10.1038/nri3150
    72. Kupper T.S., Fuhlbrigge R.C. Immune surveillance in the skin: mechanisms and clinical consequences // Nat. Rev. Immunol. 2004. Vol. 4, N 3. P. 211–222. DOI: https://doi.org/10.1038/nri1310
    73. Akiba H., Kehren J., Ducluzeau M.T., Krasteva M., Horand F., Kaiser­lian D., Kaneko F., Nicolas J.F. Skin inflammation during con­tact hypersensitivity is mediated by early recruitment of CD8+ T cytotoxic 1 cells inducing keratinocyte apoptosis // J. Immunol. 2002. Vol. 168, N 6. P. 3079–3087. DOI: https://doi.org/10.4049/jimmunol.168.6.3079
    74. Kabashima K., Weidinger S. NK cells as a possible new player in atopic dermatitis // J. Allergy Clin. Immunol. 2020. Vol. 146, N 2. P. 276–277. DOI: https://doi.org/10.1016/j.jaci.2020.04.052
    75. Hamann C.R., Egeberg A., Silverberg J.I., Gislason G., Skov L., Thyssen J.P. Association between parental autoimmune disease and atopic dermatitis in their offspring: a matched case-control study // J. Eur. Acad. Dermatol. Venereol. 2019. Vol. 33, N 6. P. 1143–1151. DOI: https://doi.org/10.1111/jdv.15413
    76. Pellefigues C. IgE autoreactivity in atopic dermatitis: paving the road for autoimmune diseases? // Antibodies (Basel). 2020. Vol. 9, N 3. P. 47. DOI: https://doi.org/10.3390/antib9030047
    77. Badloe F.M.S., De Vriese S., Coolens K., Schmidt-Weber C.B., Ring J., Gutermuth J., Kortekaas Krohn I. IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis // Clin. Transl. Allergy. 2020. Vol. 10. P. 34. DOI: https://doi.org/10.1186/s13601-020-00338-7
    78. Tanei R., Hasegawa Y. Atopic dermatitis in older adults: A viewpoint from geriatric dermatology // Geriatr. Gerontol. Int. 2016. Vol. 16, suppl. 1. P. 75–86. DOI: https://doi.org/10.1111/ggi.12771
    79. Chan A.R., Sandhu V.K., Drucker A.M., Fleming P., Lynde C.W. Adult-onset atopic dermatitis: presentations and progress // J. Cutan. Med. Surg. 2020. Vol. 24, N 3. P. 267–272. DOI: https://doi.org/10.1177/1203475420911896
    80. Kanda N., Hoashi T., Saeki H. The roles of sex hormones in the course of atopic dermatitis // Int. J. Mol. Sci. 2019. Vol. 20, N 19. P. 4660. DOI: https://doi.org/10.3390/ijms20194660
    81. Wollenberg A., Christen-Zäch S., Taieb A., Paul C., Thyssen J.P., de Bruin-Weller M., Vestergaard C., Seneschal J., Werfel T., Cork M.J., Kunz B., Fölster-Holst R., Trzeciak M., Darsow U., Szalai Z., Deleu­ran M., von Kobyletzki L., Barbarot S., Heratizadeh A., Gieler U., Hijnen D.J., Weidinger S., De Raeve L., Svensson Å., Simon D., Stalder J.F., Ring J.; European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children // J. Eur. Acad. Dermatol. Venereol. 2020. Vol. 34, N 12. P. 2717–2744. DOI: https://doi.org/10.1111/jdv.16892
    82. Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis // Acta Derm. Venereol. Suppl. (Stockh.). 1980. Vol. 92. P. 44–47.
    83. Rudzki E., Samochocki Z., Rebandel P., Saciuk E., Gałecki W., Raczka A., Szmurło A. Frequency and significance of the major and minor features of Hanifin and Rajka among patients with atopic dermatitis // Dermatology. 1994. Vol. 189, N 1. P. 41–46. DOI: https://doi.org/10.1159/000246781
    84. Micali G., Paternò V., Cannarella R., Dinotta F., Lacarrubba F. Evidence-based treatment of atopic dermatitis with topical moisturizers // G. Ital. Dermatol. Venereol. 2018. Vol. 153, N 3. P. 396–402. DOI: https://doi.org/10.23736/S0392-0488.18.05898-4
    85. Kawakami T., Soma Y. Questionnaire survey of the efficacy of emollients for adult patients with atopic dermatitis // J. Dermatol. 2011. Vol. 38, N 6. P. 531–535. DOI: https://doi.org/10.1111/j.1346-8138.2010.01052.x
    86. Sidbury R., Davis D.M., Cohen D.E., Cordoro K.M., Berger T.G., Bergman J.N., Chamlin S.L., Cooper K.D., Feldman S.R., Hani­fin J.M., Krol A., Margolis D.J., Paller A.S., Schwarzenberger K., Silverman R.A., Simpson E.L., Tom W.L., Williams H.C., Elmets C.A., Block J., Harrod C.G., Begolka W.S., Eichenfield L.F.; American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents // J. Am. Acad. Dermatol. 2014. Vol. 71, N 2. P. 327–349. DOI: https://doi.org/10.1016/j.jaad.2014.03.030
    87. Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleu­ran M., Fink-Wagner A., Gieler U., Girolomoni G., Lau S., Mura­ro A., Czarnecka-Operacz M., Schäfer T., Schmid-Grendel­mei­er P., Simon D., Szalai Z., Szepietowski J.C., Taïeb A., Torrelo A., Werfel T., Ring J.; European Dermatology Forum (EDF), the Euro­pean Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I // J. Eur. Acad. Dermatol. Venereol. 2018. Vol. 32, N 5. P. 657–682. DOI: https://doi.org/10.1111/jdv.14891
    88. Seike M., Furuya K., Omura M. et al. Histamine H4 receptor antagonist ameliorates chronic allergic contact dermatitis induced by repeated challenge // Allergy. 2010. Vol. 65. P. 319–326.
    89. Matsushita A., Seike M., Okawa H. et al. Advantage of histamine H4 receptor antagonist usage with H1 receptor antagonist for the treatment of murine allergic contact dermatitis // Exp. Dermatol. 2012. Vol. 21. P. 714–715.
    90. Akdis C.A., Simons F.E. Histamine receptors are hot in immunopharmacology // Eur. J. Pharmacol. 2006. Vol. 533. P. 69–76.
    91. Sander K., Kottke T., Stark H. Histamine H3 receptor antagonists go to clinics // Biol. Pharm. Bull. 2008. Vol. 31. P. 2163–2181.
    92. Thurmond R.L., Chen B., Dunford P.J., Greenspan A.J., Karlsson L., La D., Ward P., Xu X.L. Clinical and preclinical characterization of the histamine H4 receptor antagonist JNJ-39758979 // J. Pharmacol. Exp. Ther. 2014. Vol. 349, N 2. P. 176–184. DOI: https://doi.org/10.1124/jpet.113.211714
    93. Schaper-Gerhardt K., Rossbach K., Nikolouli E., Werfel T., Gutz­mer R., Mommert S. The role of the histamine H4 receptor in atopic dermatitis and psoriasis // Br. J. Pharmacol. 2020. Vol. 177, N 3. P. 490–502. DOI: https://doi.org/10.1111/bph.14550
    94. Murata Y., Song M., Kikuchi H., Hisamichi K., Xu X.L., Greenspan A., Kato M., Chiou C.F., Kato T., Guzzo C., Thurmond R.L., Ohtsuki M., Furue M. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis // J. Dermatol. 2015. Vol. 42, N 2. P. 129–139. DOI: https://doi.org/10.1111/1346-8138.12726
    95. Werfel T., Layton G., Yeadon M., Whitlock L., Osterloh I., Jimenez P., Liu W., Lynch V., Asher A., Tsianakas A., Purkins L. Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis // J. Allergy Clin. Immunol. 2019. Vol. 143, N 5. P. 1830–1837.e4. DOI: https://doi.org/10.1016/j.jaci.2018.07.047
    96. Väkevä L., Niemelä S., Lauha M., Pasternack R., Hannuksela-Svahn A., Hjerppe A., Joensuu A., Soronen M., Ylianttila L., Pas­tila R., Kautiainen H., Snellman E., Grönroos M., Karppinen T. Narrowband ultraviolet B phototherapy improves quality of life of psoriasis and atopic dermatitis patients up to 3 months: Re­sults from an observational multicenter study // Photodermatol. Photoimmunol. Photomed. 2019. Vol. 35, N 5. P. 332–338. DOI: https://doi.org/10.1111/phpp.12479
    97. Simpson E.L., Bieber T., Guttman-Yassky E., Beck L.A., Blauvelt A., Cork M.J., Silverberg J.I., Deleuran M., Kataoka Y., Lacour J.P., Kingo K., Worm M., Poulin Y., Wollenberg A., Soo Y., Graham N.M., Pirozzi G., Akinlade B., Staudinger H., Mastey V., Eckert L., Gadkari A., Stahl N., Yancopoulos G.D., Ardeleanu M.; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis // N. Engl. J. Med. 2016. Vol. 375, N 24. P. 2335–2348. DOI: https://doi.org/10.1056/NEJMoa1610020
    98. Simpson E.L., Paller A.S., Siegfried E.C., Boguniewicz M., Sher L., Gooderham M.J., Beck L.A., Guttman-Yassky E., Pari­ser D., Blau­velt A., Weisman J., Lockshin B., Hultsch T., Zhang Q., Ka­mal M.A., Davis J.D., Akinlade B., Staudinger H., Hamil­ton J.D., Graham NMH, Pirozzi G., Gadkari A., Eckert L., Stahl N., Yanco­poulos G.D., Ruddy M., Bansal A. Efficacy and safety of dupilumab in adoles­cents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial // JAMA Dermatol. 2020. Vol. 156, N 1. P. 44–56. DOI: https://doi.org/10.1001/jamadermatol.2019.3336
    99. Jin S.Y., Lim W.S., Sung N.H., Cheong K.A., Lee A.Y. Combination of glucosamine and low-dose cyclosporine for atopic dermatitis treatment: a randomized, placebo-controlled, double-blind, parallel clinical trial // Dermatol. Ther. 2015. Vol. 28, N 1. P. 44–51. DOI: https://doi.org/10.1111/dth.12163
    100. Fyhrquist N., Muirhead G., Prast-Nielsen S., Jeanmougin M., Olah P., Skoog T., Jules-Clement G., Feld M., Barrientos-So­­­mar­­­ri­bas M., Sinkko H., van den Bogaard E.H., Zeeuwen PLJM, Rik­ken G., Schalkwijk J., Niehues H., Däubener W., Eller S.K., Alexander H., Pennino D., Suomela S., Tessas I., Lybeck E., Baran A.M., Dar­ban H., Gangwar R.S., Gerstel U., Jahn K., Karisola P., Yan L., Hansmann B., Katayama S., Meller S., Bylesjö M., Hupé P., Levi-Schaffer F., Greco D., Ranki A., Schröder J.M., Barker J., Kere J., Tsoka S., Lauerma A., Soumelis V., Nestle F.O., Homey B., Andersson B., Alenius H. Microbe-host interplay in atopic dermatitis and psoriasis // Nat. Commun. 2019. Vol. 10, N 1. P. 4703. DOI: https://doi.org/10.1038/s41467-019-12253-y
    101. Nowicka D., Nawrot U. Contribution of Malassezia spp. to the development of atopic dermatitis // Mycoses. 2019. Vol. 62, N 7. P. 588–596. DOI: https://doi.org/10.1111/myc.12913
    102. Brodská P., Panzner P., Pizinger K., Schmid-Grendelmeier P. IgE-mediated sensitization to malassezia in atopic dermatitis: more common in male patients and in head and neck type // Dermatitis. 2014. Vol. 25, N 3. P. 120–126. DOI: https://doi.org/10.1097/DER.0000000000000040
    103. Sonesson A., Bartosik J., Christiansen J. et al. Sensitization to skin-associated microorganisms in adult patients with atopic dermatitis is of importance for disease severity // Acta Derm. Venereol. 2013. Vol. 93. P. 340–345.
    104. Кубанов А.А., Намазова-Баранова Л.С., Хаитов Р.М. и др. Атопический дерматит. Российский аллергологический журнал. 2021. Т. 18. N 3. С. 44–92. DOI: https://doi.org/10.36691/RJA1474
    105. Nankervis H., Pynn E.V., Boyle R.J., Rushton L., Williams H.C., Hewson D.M., Platts-Mills T. House dust mite reduction and avoidance measures for treating eczema // Cochrane Database Syst. Rev. 2015. Vol. 1. Article ID CD008426. DOI: https://doi.org/10.1002/14651858.CD008426.pub2
    106. Holm J.G., Thomsen S.F. Omalizumab for atopic dermatitis: evidence for and against its use // G. Ital. Dermatol. Venereol. 2019. Vol. 154, N 4. P. 480–487. DOI: https://doi.org/10.23736/S0392-0488.19.06302-8
    107. Wollenberg A., Howell M.D., Guttman-Yassky E., Silverberg J.I., Kell C., Ranade K., Moate R., van der Merwe R. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb // J. Allergy Clin. Immunol. 2019. Vol. 143, N 1. P. 135–141. DOI: https://doi.org/10.1016/j.jaci.2018.05.029
    108. Guttman-Yassky E., Blauvelt A., Eichenfield L.F., Paller A.S., Armst­rong A.W., Drew J., Gopalan R., Simpson E.L. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial // JAMA Dermatol. 2020. Vol. 156, N 4. P. 411–420. DOI: https://doi.org/10.1001/jamadermatol.2020.0079
    109. Simpson E.L., Parnes J.R., She D., Crouch S., Rees W., Mo M., van der Merwe R. Tezepelumab, an anti-thymic stromal lympho­­poie­tin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial // J. Am. Acad. Dermatol. 2019. Vol. 80, N 4. P. 1013–1021. DOI: https://doi.org/10.1016/j.jaad.2018.11.059
    110. Kabashima K., Matsumura T., Komazaki H., Kawashima M.; Nemolizumab-JP01 Study Group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus // N. Engl. J. Med. 2020. Vol. 383, N 2. P. 141–150. DOI: https://doi.org/10.1056/NEJMoa1917006
    111. Khattri S., Brunner P.M., Garcet S., Finney R., Cohen S.R., Oliva M., Dutt R., Fuentes-Duculan J., Zheng X., Li X., Bonifacio K.M., Kunj­ravia N., Coats I., Cueto I., Gilleaudeau P., Sullivan-Whalen M., Suárez-Fariñas M., Krueger J.G., Guttman-Yassky E. Efficacy and safety of ustekinumab treatment in adults with moderate-to-­severe atopic dermatitis // Exp. Dermatol. 2017. Vol. 26, N 1. P. 28–35. DOI: https://doi.org/10.1111/exd.13112
    112. Ungar B., Pavel A.B., Li R., Kimmel G., Nia J., Hashim P., Kim H.J., Chima M., Vekaria A.S., Estrada Y., Xu H., Peng X., Singer G.K., Baum D., Mansouri Y., Taliercio M., Guttman-Yassky E. Phase 2
      randomized, double-blind study of IL-17 targeting with secuki­numab in atopic dermatitis // J. Allergy Clin. Immunol. 2021. Vol. 147, N 1. P. 394–397. DOI: https://doi.org/10.1016/j.jaci.2020.04.055
    113. Guttman-Yassky E., Brunner P.M., Neumann A.U., Khattri S., Pavel A.B., Malik K., Singer G.K., Baum D., Gilleaudeau P., Sullivan-Whalen M., Rose S., Jim On S., Li X., Fuentes-Duculan J., Estrada Y., Garcet S., Traidl-Hoffmann C., Krueger J.G., Leb­wohl M.G. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately cont­rol­led by conventional treatments: A randomized, double-blind, phase 2a trial // J. Am. Acad. Dermatol. 2018. Vol. 78, N 5. P. 872–881.e6. DOI: https://doi.org/10.1016/j.jaad.2018.01.016
    114. A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Rising Up) // ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT03661138.
    115. Guttman-Yassky, Emma et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials // Lancet (London, England). Vol. 397, N 10290 (2021). P. 2151–2168.
    116. Silverberg JI, de Bruin-Weller M, Bieber T, Soong W, Kaba­shi­ma K, Costanzo A, Rosmarin D, Lynde C, Liu J, Gamelli A, Zeng J, Ladizinski B, Chu AD, Reich K, Upadacitinib plus topical corticosteroids in atopic dermatitis: week-52 AD Up study results // J. Allergy Clin. Immunol. (2021). DOI: https://doi.org/10.1016/j.jaci.2021.07.036
    117. Bissonnette R., Papp K.A., Poulin Y., Gooderham M., Raman M., Mallbris L., Wang C., Purohit V., Mamolo C., Papacharalambous J., Ports W.C. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial // Br. J. Dermatol. 2016. Vol. 175, N 5. P. 902–911. DOI: https://doi.org/10.1111/bjd.14871
    118. Guttman-Yassky E., Thaçi D., Pangan A.L., Hong H.C., Papp K.A., Reich K., Beck L.A., Mohamed M.F., Othman A.A., Anderson J.K., Gu Y., Teixeira H.D., Silverberg J.I. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial // J. Allergy Clin. Immunol. 2020. Vol. 145, N 3. P. 877–884. DOI: https://doi.org/10.1016/j.jaci.2019.11.025
    119. Simpson E.L., Sinclair R., Forman S., Wollenberg A., Aschoff R., Cork M., Bieber T., Thyssen J.P., Yosipovitch G., Flohr C., Mag­nolo N., Maari C., Feeney C., Biswas P., Tatulych S., Valdez H., Rojo R. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial // Lancet. 2020. Vol. 396, N 10246. P. 255–266. DOI: https://doi.org/10.1016/S0140-6736(20)30732-7
    120. Simon D., Hösli S., Kostylina G., Yawalkar N., Simon H.U. Anti-CD20 (rituximab) treatment improves atopic eczema // J. Allergy Clin. Immunol. 2008. Vol. 121. P. 122–128.
    121. Kasperkiewicz M., Schmidt E., Ludwig R.J., Zillikens D. Targeting ige antibodies by immunoadsorption in atopic dermatitis // Front. Immunol. 2018. Vol. 9. P. 254. DOI: https://doi.org/10.3389/fimmu.2018.00254
    122. Vakharia P.P., Silverberg J.I. New therapies for atopic dermatitis: Additional treatment classes // J. Am. Acad. Dermatol. 2018. Vol. 78, N 3, suppl 1. P. S76–S83. DOI: https://doi.org/10.1016/j.jaad.2017.12.024
    123. Simpson E.L., Imafuku S., Poulin Y., Ungar B., Zhou L., Malik K., Wen H.C., Xu H., Estrada Y.D., Peng X., Chen M., Shah N., Suarez-Farinas M., Pavel A.B., Nograles K., Guttman-Yassky E. A phase 2 randomized trial of apremilast in patients with atopic dermatitis // J. Invest. Dermatol. 2019. Vol. 139, N 5. P. 1063–1072. DOI: https://doi.org/10.1016/j.jid.2018.10.043.
    124. Chin W.K., Lee SWH. A systematic review on the off-label use of montelukast in atopic dermatitis treatment // Int. J. Clin. Pharm. 2018. Vol. 40, N 5. P. 963–976. DOI: https://doi.org/10.1007/s11096-018-0655-3

Для продолжения работы требуется вход / регистрация